摘要
目的探讨行重组人p53腺病毒(rAd-p53)瘤内注射前后鼻咽癌原发灶中淋巴管的表达情况。方法 63例确诊中晚期鼻咽癌患者随机分为两组。治疗组32例行rAd-p53瘤内注射+同步放化疗,对照组31例行单纯同步放化疗。分别收集两组的临床资料,采集rAd-p53瘤内注射前后鼻咽部瘤体活组织标本,采用免疫组化二步法检测鼻咽癌原发灶组织中淋巴管D2-40的表达情况。结果两组D240蛋白表达差异无统计学意义(P>0.05)。两组治疗后D2-40蛋白表达均较治疗前升高,差异有统计学意义(P<0.01)。结论 rAd-p53可能通过某种机制抑制鼻咽癌淋巴道转移。
Objective To evaluate the expression of lymphatic vessels of in primary foci of nasopharyngeal carcinoma（NPC） after intratumoral injection of recombinant human p53 adenovirus （rAd-p53）. Methods Sixty- three patients with advanced nasopharyngeal carcinoma were randomly divided into 2 groups. Treatment group （ n = 32） received rAd-p53 intratumora/injection, concurrent radiotherapy and chemotherapy. The control group （n = 31 ） received concurrent radiotherapy and chemotherapy. Clinical data were collected, and before and after intratumoral injection of rAd-p53 nasopharyngeal tumor biopsy specimens were collected. Two-step immunohistochemical detection was used to test D2-40 expression in primary foci of NPC. Results After treatment, D2-40 expression was significant- ly higher than that before treatment in two groups （P 〈 0. 05 or P 〈 0. 01 ）. The difference of D2-40 expression be- tween two groups was not statistically significant （P 〉 0. 05）. Conclusion rAd-p53 may inhibite lymph node metas- tasis of nasopharyngeal carcinoma by some mechanism.
出处
《中国临床新医学》
2012年第9期821-823,共3页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
基金
广西卫生厅科研课题(编号:Z2008043)
广西医疗卫生重点科研课题(编号:重200721)
关键词
鼻咽癌
RAD-P53
淋巴管
Nasopharyngeal carcinoma
rAd-p53
Lymphatic vessels
